ClinicalTrials.gg
CompletedNCT01433497Updated Apr 8, 2020

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

A Phase 3 interventional study of Masitinib and Placebo in Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive and Multiple Sclerosis, Relapse Free, sponsored by AB Science. Completed at 8 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
656
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France — 4 open to participants now, 10 under way, 8 of them phase 3. Multiple Sclerosis, Chronic Progressive · France.

Enrollment
15th of 28
656 · median 696
Started
2011
with 3 others
Phase 3
18 of 32
3 open now
Registered
5th of 32
by date
Lead sponsor
2 of 32
AB Science

Among the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2011, is one of 18 in phase 3, and was the 5th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

4 of the 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Multiple Sclerosis, Chronic Progressive with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor that is thought to exert a neuroprotective effect through its activity on mast cells and other non-neuronal cells of the central nervous system, with subsequent modulation of inflammatory and neurodegenerative processes. The objective of this study is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day versus matched placebo, or masitinib at 4.5 mg/kg/day with a dose escalation to 6 mg/kg/day after 3 months of treatment versus matched placebo, in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis. Approximately 600 patients will be randomized into four treatment groups with a 2:2:1:1 design. The primary outcome measure is the Expanded Disability Status Scale (EDSS) after 96 weeks of treatment in the overall study population with subgroup analysis performed in stratum (primary progressive multiple sclerosis / secondary progressive multiple sclerosis).

03

Conditions studied

  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Relapse Free

Keywords

  • multiple sclerosis
  • primary progressive
  • relapse-free
  • secondary progressive
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Patient suffering from either primary progressive or secondary progressive multiple sclerosis without relapse within 2 years before inclusion according to the revised McDonald's criteria.

Main exclusion criteria:

  • Patient suffering from a disease other than MS that would better explain the patient's neurological clinical signs and symptoms and/or MRI lesions
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
656 participants (actual)

Study arms

  • Experimental
    Experimental Arm A

    Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.

    Drug: Masitinib

  • Experimental
    Experimental Arm B

    Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.

    Drug: Masitinib

  • Placebo comparator
    Placebo Comparator A

    Participants receive placebo given orally twice daily.

    Drug: Placebo

  • Placebo comparator
    Placebo Comparator B

    Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.

    Drug: Placebo

Interventions

  • Also known as: AB1010

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. EDSS

    Expanded Disability Status Scale (EDSS) after 96 weeks of treatment

    Time frame: 96 weeks

Secondary outcomes

  1. MSQOL-54

    Multiple Sclerosis Quality of Life 54 items (MSQOL-54)

    Time frame: 96 weeks

  2. MSFC

    Multiple Sclerosis Functional Composite (MSFC)

    Time frame: 96 weeks

07

Study locations

8 sites
  • "St. Ivan Rilski" University Multiprofile Hospital for Active Treatment
    Sofia, 1431, Bulgaria
  • GHICL hopital ST vincent de Paul
    Lille, 59020, France
  • Hôpital de Gui de Chauliac
    Montpellier, 34295, France
  • Universitätsklinikum Gießen und Marburg
    Marburg, D-35033, Germany
  • Rehibilitation Center "KENTAVROS"
    Volos, 382 21, Greece
  • KO-MED Centra Kliniczne Lublin II
    Lublin, 20-362, Poland
  • Centrul Medical Clubul Sănătăţii
    Campulung, 115100, Romania
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
08

References and documents

Publications

  • Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M; AB07002 Study Group. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial. Neurol Neuroimmunol Neuroinflamm. 2022 Feb 21;9(3):e1148. doi: 10.1212/NXI.0000000000001148. Print 2022 May. PubMed 35190477 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Sep 2019, 97 months.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 97 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Sep 14, 2011
StartActual
Aug 2011
Primary completionActual
Sep 2019
CompletionActual
Feb 2020
Results delay requested
Mar 30, 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433497
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Sep 14, 2011
Start date
Aug 2011
Primary completion
Sep 2019
Completion
Feb 2020
Last update
Apr 8, 2020

Study contacts

Patrick Vermersch, MD, PhD
principal investigator · Hôpital Salengro, Lille, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion